Ferroportin Gene Polymorphism, Ferritin, and TIBC Levels Associated with the Severity of COVID-19 among patients: A Sequencing Analysis

Ban Adnan Hatem, Ferdous A Jabir

Abstract


Background: SARS-CoV-2 may also be termed a high-load virus due to its rapid spread in the bloodstream. In vitro studies verify that iron chelators can inhibit the virus, indicating iron's key component in viral replication. What's more, increased apoptosis (ferroptosis) due to intracellular accretion of iron has been discovered in biopsy specimens of COVID-19 patients. Unlike harsh pneumonitis, COVID-19 does not demonstrate a hepcidin-initiated accretion of iron at foci of infection, suggesting a different iron metabolism profile.

Methods: This work explored COVID-19 risk and severity according to Ferroportin gene polymorphisms, SNPs rs3811621 and rs10202029. Infected and recovered individuals' samples were utilized for genotypic analysis to observe possible genetic associations.

Result: There were no notable associations of SNP rs3811621 and SNP rs10202029 both with susceptibility to COVID-19, and harshness of the disease. Frequencies of genotype between patient and recovery groups did not differ. Ferritin values, however, were significantly different between mild, severe, and recovery cases. Total iron-binding capacity (TIBC) was significantly lower in recovery subjects than in moderate or severe disease subjects, a predictable and significant finding.

Conclusion: Ferroportin polymorphisms (rs3811621 and rs10202029) do not appear to influence COVID-19 susceptibility and severity. In spite of that, variations in ferritin and TIBC across different patient populations demonstrate their significance as biomarkers in defining iron metabolism during and after infection.

Keywords: COVID-19; Ferroportin; ferritin; polymorphism; Sequencing; TIBC


Full Text:

PDF

References


Donovan A, Brownlie A, Zhou YI, Shepard J, Pratt SJ, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature, (2000); 403(6771): 776-781.

Ward DM, Kaplan J. Ferroportin-mediated iron transport: expression and regulation. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, (2012); 1823(9): 1426-1433.

Reid KM, Tsung A, Kaizu T, Jeyabalan G, Ikeda A, et al. Liver I/R injury is improved by the arginase inhibitor, Nω-hydroxy-nor-L-arginine (nor-NOHA). American Journal of Physiology-Gastrointestinal and Liver Physiology, (2007); 292(2): G512-G517.

Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, (2004); 306(5704): 2090-2093.

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, (2020); 579(7798): 270-273.

Agarwal AK, Yee J. Henry Ford Health Scholarly Commons. Advances in Chronic Kidney Disease, (2019); 26(4): 298-305.

Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica, (2020); 105(2): 260-272.

Yamanishi H, Iyama S, Yamaguchi Y, Kanakura Y, Iwatani Y. Total iron-binding capacity calculated from serum transferrin concentration or serum iron concentration and unsaturated iron-binding capacity. Clinical Chemistry, (2003); 49(1): 175-178.

Xin W, Weiwei W, Hongtao S, Wenjuan S, Changhua L. The acute and chronic effects of monosodium L-glutamate on serum iron and total iron-binding capacity in the jugular artery and vein of pigs. Biological Trace Element Research, (2013); 153(1): 191-195.

Kamble CG, Mulay DM, Tamboli MA, Sonawane RS. Study of Hemoglobin Count, Iron and Total Iron Binding Capacity variation pattern in Sickle Cell Disease. Pravara Medical Review, (2021); 13(1): 31-37.

Cavezzi A, Troiani E, Corrao S. COVID-19: Hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Clinics and Practice, (2020); 10(2): 24-30.

Chifman J, Laubenbacher R, Torti SV (2014) A systems biology approach to iron metabolism. A Systems Biology Approach to Blood. pp. 201-225.

Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics, (2014); 6(4): 748-773.

Daher R, Manceau H, Karim Z. Iron metabolism and the role of the iron-regulating hormone hepcidin in health and disease. La Presse Médicale, (2017); 46(12): e272-e278.

Alipour R, Hashemi SH, Mikaeili F. Serum iron level in patients with COVID-19: a case report study. International Journal of Research in Medical Sciences, (2020); 8(7): 2658.

Cortese-Krott MM, Kuhnle GG, Dyson A, Fernandez BO, Grman M, et al. The reactive species interactome: evolutionary emergence, biological significance, and opportunities for redox metabolomics and personalized medicine. Antioxidants & Redox Signaling, (2017); 27(10): 684-712.

De Benoist B, Cogswell M, Egli I, McLean E. Worldwide prevalence of anaemia 1993-2005; WHO Global Database of anaemia. WHO Press, (2008); 1-40.

Wessling-Resnick M. Iron homeostasis and the inflammatory response. Annual Review of Nutrition, (2010); 30(1): 105-122.




DOI: http://dx.doi.org/10.62940/als.v12i4.2150

Refbacks

  • There are currently no refbacks.